Head and Neck Neoplasms Clinical Trial
Official title:
F-18 Fluorothymidine (FLT) PET Imaging for Early Evaluation of Response to Chemoradiation Therapy in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)
This is an imaging protocol only, not a therapeutic study.
The primary goal of the proposed study is to examine the utility of a new imaging study,
Positron Emission Tomography with F-18 Fluorothymidine (FLT PET), in the early treatment
evaluation of head and neck cancer. FLT uptake in the tumor correlates with the rate of cell
proliferation. It is therefore hoped that changes in tumor FLT uptake after therapy will
reflect change in the number of actively dividing tumor cells and will provide early
assessment of treatment response.
Research subjects will undergo one PET scan with FLT. The scan is done prior to any
therapeutic intervention (radiation or chemotherapy) can be obtained up to 30 days prior to
the start of therapy. The uptake of FLT in the tumor will be analyzed to see if it can be
used as a predictor of treatment efficacy and/or outcome.
There is an optional biopsy component to this study. Should the attending physicians
(primarily the otolaryngologists) believe that the subject can safely undergo an outpatient
biopsy, and the subject agrees, a biopsy is performed. The biopsy will be done within 30 days
prior to treatment, similar to FLT PET scans. Tissue from the biopsy will be analyzed for
markers of cellular proliferation and these markers will be correlated with the findings of
FLT PET scan.
There will be a 2-year clinical follow-up to assess for treatment outcomes, local control,
and overall survival.
There are approximately 40,000 new cases of head and neck cancer each year in the United
States. Approximately two thirds of these patients present with locally advanced disease with
either large disease at the primary site and/or spread to regional lymph node levels.
Treatment options include surgery, radiotherapy, and chemotherapy, usually applied in
combination for advanced disease. Despite aggressive treatment, the 5-year survival for
locally advanced disease remains poor (overall, approximately 50%). To increase the efficacy
of locoregional therapy, different treatment maneuvers are used including increased radiation
dose, concurrent use of chemotherapy and radiation therapy and high dose intra-arterial
chemotherapy. Unfortunately, the increased intensity of combined treatment also leads to
greater treatment related morbidity and mortality. It is currently difficult to predict who
will benefit from intensive chemoradiotherapy and who would be most effectively treated with
other combinations such as surgery and postoperative radiotherapy.
It is predictable that the most immediate signal of a successful antitumor therapeutic regime
will be a decrease in cellular proliferation in the tumor. Therefore, a tracer, which is
taken up into and retained in cells as a function of their proliferative activity, should
provide rapid information as to the effectiveness of the treatment. FLT is an ideal tracer in
this setting as its uptake is a function of thymidine kinase activity. Thymidine kinase
activity is an established marker of cellular proliferation. FLT can be imaged with a PET
scanner and the FLT uptake in the tumor can be reliably quantified. Preliminary studies
including at our institution also confirm accumulation of FLT in untreated head and neck
cancers. The objective of our study is to evaluate the utility of FLT PET imaging in
predicting the outcome of treatment in terms of locoregional control and disease-free
survival in patients (i.e., progression free survival) with head and neck cancer as well as
overall survival.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05980598 -
TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
Completed |
NCT02548377 -
Remote Ischemic Preconditioning in Head and Neck Cancer Reconstruction - A Randomized Controlled Trial
|
N/A | |
Active, not recruiting |
NCT02229656 -
Olaparib and Radiotherapy in Head and Neck Cancer
|
Phase 1 | |
Not yet recruiting |
NCT06347185 -
Simultaneous Care in Recurrent and/or Metastatic Head and Neck Cancer: the SupCare Study
|
N/A | |
Not yet recruiting |
NCT06289049 -
Heavy Strength Training in Head and Neck Cancer Survivors
|
Phase 2 | |
Terminated |
NCT02975739 -
Feasibility of Holmium-166 Micro Brachytherapy in Head and Neck Tumors
|
N/A | |
Recruiting |
NCT00982436 -
Neoadjuvant Cisplatin/Docetaxel (CDDP/TXT) and Chemoradiation for Head and Neck Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01025518 -
DAHANCA 25A: Resistance Training and Dietary Supplements as Intervention for Regaining Muscle Mass Following Radiotherapy in Head and Neck Cancer Patients
|
N/A | |
Active, not recruiting |
NCT00248235 -
Resistance Exercise Training for the Shoulder and Neck Following Surgery for Head and Neck Cancer
|
Phase 2/Phase 3 | |
Terminated |
NCT00073450 -
Study of Lonafarnib in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck (Study P02530)
|
Phase 2 | |
Completed |
NCT00135161 -
Feasibility Study of Incorporating 18F-FDG-PET Imaging in Radiotherapy for Head and Neck Cancer
|
Phase 1 | |
Not yet recruiting |
NCT06458517 -
Evaluation of Two Methods of Administration of Photobiomodulation in the Context of the Prevention and Treatment of Mucositis Induced by Radiotherapy, During the Treatment of Head and Neck Cancers
|
N/A | |
Completed |
NCT05269342 -
Nurse-led Exercise Improves Shoulder Pain, Shoulder Disability, and Quality of Life in Head and Neck Cancer
|
N/A | |
Recruiting |
NCT05544136 -
A Study of Decreasing Radiation Therapy and Chemotherapy in People With Head and Neck Cancer
|
Phase 2 | |
Terminated |
NCT03286972 -
PET/MRI to Enhance Precision Guidance in Head and Neck Radiation Treatment Planning
|
||
Recruiting |
NCT04435938 -
A Study of SBRT for Squamous Cell Carcinoma of the Head and Neck
|
Phase 2 | |
Recruiting |
NCT03678649 -
A Prospective Randomized Trial of Capecitabine Treatment in Patients With HNSCC
|
Phase 2 | |
Recruiting |
NCT03975465 -
EMST and Swallowing in Long-Term Survivors of HNCA
|
N/A | |
Completed |
NCT06446570 -
Phase II Study of Durvalumab(MEDI4736) + Tremelimumab in Pulmonary Sarcomatoid Carcinoma
|
Phase 2 | |
Completed |
NCT03292250 -
Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)]
|
Phase 2 |